Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc.verified

INTI

Price:

$0.05

Market Cap:

$8.63M

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.

Industry

Biotechnology

IPO Date

2013-09-13

Stock Exchange

OTC

Ticker

INTI

The Enterprise Value as of December 2025 (TTM) for Inhibitor Therapeutics, Inc. (INTI) is 5.72M

According to Inhibitor Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 5.72M. This represents a change of 24.74% compared to the average of 4.59M of the last 4 quarters.

Inhibitor Therapeutics, Inc. (INTI) Historical Enterprise Value (quarterly & annually)

How has INTI Enterprise Value performed in the past?

The mean historical Enterprise Value of Inhibitor Therapeutics, Inc. over the last ten years is 37.09M. The current 5.72M Enterprise Value has changed 1.44% with respect to the historical average. Over the past ten years (40 quarters), INTI's Enterprise Value was at its highest in in the September 2017 quarter at 154.34M. The Enterprise Value was at its lowest in in the June 2023 quarter at -3737511.00.

Quarterly (TTM)
Annual

Average

37.09M

Median

22.90M

Minimum

4.75M

Maximum

105.73M

Inhibitor Therapeutics, Inc. (INTI) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Inhibitor Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 334.37%

Maximum Annual Enterprise Value = 105.73M

Minimum Annual Increase = -79.44%

Minimum Annual Enterprise Value = 4.75M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20244.75M-6.59%
20235.08M-79.44%
202224.71M-56.37%
202156.64M334.37%
202013.04M-29.62%
201918.53M-12.11%
201821.08M-77.01%
201791.68M-13.29%
2016105.73M256.72%
201529.64M155.06%

Inhibitor Therapeutics, Inc. (INTI) Average Enterprise Value

How has INTI Enterprise Value performed in the past?

The current Enterprise Value of Inhibitor Therapeutics, Inc. (INTI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

11.51M

5-year avg

20.84M

10-year avg

37.09M

Inhibitor Therapeutics, Inc. (INTI) Enterprise Value vs. Peers

How is INTI’s Enterprise Value compared to its peers?

Inhibitor Therapeutics, Inc.’s Enterprise Value is greater than LianBio (-40025352.00), less than Oxford BioDynamics Plc (6.37M), greater than Devonian Health Group Inc. (5.00M), greater than Chimeric Therapeutics Limited (5.17M), greater than Quantum Genomics S.A. (4.17M), less than Curative Biotechnology, Inc. (10.95M), greater than Nymox Pharmaceutical Corporation (4.84M), less than BetterLife Pharma Inc. (9.64M), less than PharmaTher Holdings Ltd. (10.45M), less than Nass Valley Gateway Ltd. (12.82M),

Build a custom stock screener for Inhibitor Therapeutics, Inc. (INTI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibitor Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Inhibitor Therapeutics, Inc. (INTI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Inhibitor Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Inhibitor Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Inhibitor Therapeutics, Inc. (INTI)?

What is the 3-year average Enterprise Value for Inhibitor Therapeutics, Inc. (INTI)?

What is the 5-year average Enterprise Value for Inhibitor Therapeutics, Inc. (INTI)?

How does the current Enterprise Value for Inhibitor Therapeutics, Inc. (INTI) compare to its historical average?